Leuprorelin 1-Month Depot as Neoadjuvant Therapy for Prostate Cancer

1998 ◽  
Vol 60 (Suppl. 2) ◽  
pp. 11-17
Author(s):  
Domenico Prezioso ◽  
Tullio Lotti ◽  
Rodolfo Montironi ◽  
Mario Polito
Keyword(s):  
Prostate Cancer ◽  
Neoadjuvant Therapy

Adjuvant and neoadjuvant therapy in prostate cancer

2001 ◽  
Vol 28 (1) ◽  
pp. 3-12 ◽  
Author(s):  
Christopher Chay ◽  
David C. Smith
Keyword(s):  
Prostate Cancer ◽  
Neoadjuvant Therapy ◽  
Adjuvant And Neoadjuvant Therapy

scholarly journals SIGNIFICANCE OF NEOADJUVANT THERAPY FOR PROSTATE CANCER

1997 ◽  
Vol 88 (9) ◽  
pp. 769-777
Author(s):  
Kiyoki Okada ◽  
Takahiko Hachiya
Keyword(s):  
Prostate Cancer ◽  
Neoadjuvant Therapy

scholarly journals Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer–A Pilot Study

2020 ◽  
Vol 27 (10) ◽  
pp. 1432-1439 ◽  
Author(s):  
Fiona M. Fennessy ◽  
Andriy Fedorov ◽  
Mark G. Vangel ◽  
Robert V. Mulkern ◽  
Maria Tretiakova ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Neoadjuvant Therapy ◽  
Multiparametric Mri ◽  
Localized Prostate Cancer

Neoadjuvant therapy prior to radical prostatectomy in high-risk prostate cancer patients

2018 ◽  
Vol 6 (4) ◽  
pp. 17-25
Author(s):  
M.V.Berkut M.V.Berkut ◽  
◽  
N.N.Buevich N.N.Buevich ◽  
S.A.Reva S.A.Reva ◽  
S.B.Petrov S.B.Petrov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: A multi-institutional analysis.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. e543-e543
Author(s):  
Takuya Koie ◽  
Teppei Ookubo ◽  
Koji Mitsuzuka ◽  
Shintaro Narita ◽  
Takamitsu Inoue ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
High Risk ◽  
Neoadjuvant Therapy ◽  
Lymph Node Dissection ◽  
Biochemical Recurrence ◽  
Node Dissection ◽  
Extended Lymph Node Dissection ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

e543 Background: The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) in high-risk Pca patients treated with neoadjuvant therapy comprising a luteinizing-hormone-releasing hormone (LHRH) agonist plus low-dose estramustine phosphate (EMP) (LHRH+EMP) followed by radical prostatectomy (RP). The aim of this study was to assess whether neoadjuvant LHRH+EMP confers an oncological benefit for high-risk Pca compared to extended lymph node dissection (e-PLND). Methods: The Michinoku Urological Cancer Study Group database contained the data of 2403 consecutive Pca patients treated with RP at 4 institutes between March 2000 and December 2014. In the e-PLND group, we identified 238 high-risk Pca patients who underwent RP and e-PLND, with lymphatic tissue removal around the obturator and the external iliac regions, and hypogastric lymph node dissection. The neoadjuvant therapy with limited PLND (l-PLND) group included 280 high-risk Pca patients who underwent RP and removal of the obturator node chain between September 2005 and June 2014 at Hirosaki University. The neoadjuvant LHRH+EMP therapy included the administration of 280 mg/day of LHRH and EMP for 6 months before RP. The outcome measure was BRFS. Results: The 5-year BRFS rates for the neoadjuvant therapy with l-PLND group and e-PLND group were 84.9% and 54.7%, respectively ( P < 0.0001). The operative time was significantly longer in the e-PLND group compared to that of the neoadjuvant therapy with l-PLND group. Grade 3/4 surgery-related complications were not identified in both groups. Conclusions: Although the present study was not randomized, neoadjuvant LHRH+EMP therapy followed by RP might reduce the risk of biochemical recurrence.

Sign in / Sign up

Export Citation Format

Share Document